Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Treat and Resect Feasibility Study of the CellFX System for the Treatment of Low-Risk Basal Cell Carcinoma (BCC) Lesions

NCT04918381 is registered in ClinicalTrials.gov with Pulse Biosciences, Inc. as lead sponsor.

NCT NCT04918381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Treat and Resect Feasibility Study of the CellFX System for the Treatment of Low-Risk Basal Cell Carcinoma (BCC) Lesions
Lead sponsor
Pulse Biosciences, Inc.
Phase
Not applicable
Overall status
Completed
Start date
June 2, 2021
Completion date
July 22, 2022
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bcc, bcc - basal cell carcinoma, excision margin